Biohaven Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Biohaven Ltd. (BHVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $8.52 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-10
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $8.67, a 66.97% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $26.25, a 14.83% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $30.82, a 174.44% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $11.23.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $24.25, a 21.16% decline from fiscal 2024.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $30.76, a 70.79% increase from fiscal 2023.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $18.01, a 262.37% increase from fiscal 2022.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $4.97.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.52 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $8.67 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $24.25 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $24.25 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $25.04 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $26.25 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | $30.76 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $30.60 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $30.76 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $30.82 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $18.01 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $18.01 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $10.16 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $11.23 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $4.97 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |